Week 97 Review - Buffer is re-instated

A really good week with some stunning rises that even a typically feeble Friday couldn't undo. The portfolio value increased by £1,697 to £65,130 and re-instated a decent buffer of £3,453.

No double-digit losers yet again. The worst performer was frustratingly OPTI:Optibiotix which dropped 4% following news of a 3-year deal to supply LP_LDL^® to HLH Biopharma. The first of many deals and guaranteed income, so what happens? The share price drops! Sometimes my patience is tried to the very extreme!

There were loads of non-movers this week and very few losses, but OPTI:Optibiotix at nearly 30% of my holding has quite a big negative effect when it drops. Fortunately the rest of the team were in much better spirits.

AMYT:Amryt Pharma continued to rise, climbing another 7% and now making paper profits of £1,938 (31%).

TLOU:Tlou Energy is worth a mention, as it's been lagging lately but gained 9% this week and despite me selling a big chunk a while ago, the remainder are still up by 18% but that's only £98 profit.

First double-digit riser should have been Share of the week, as with a 25% rise on the back of a great trading statement, CWR:Ceres Power are now £594 (33%) up.

Share of the Week shouldn't be a surprise. I was worried when it got to 70p that there would be a trace back, and I know a lot of people sold. This week IQE:IQE increased in value by a staggering 37% in my ISA and is now making £3,271 (167%) profit. In my SIPP the later purchase is up by £1,785 (67%). The more I look at the potential sales the more excited I get. If only they would switch to the main market, they might get taken more seriously by the big institutions, and then anything could happen.

The gap is almost back to the most it's ever been.

The share and ISA portfolios look like this

			Weekly Change
Portfolio cost	£43,339.81		+£0
Portfolio sell value (bid price - commission)	£44,650.22	(3%)	+£1,432.35
Potential profits	£6,792.95		+£1,599.67
Yr 2 Dividends	£486.29		+£0
Yr 2 Profit from sales	£2,401.06		+£0
Yr 2 Average monthly cash profit	£274.43	(7.6%)	-£6.24
Total Dividends	£1,154.22		+£0
Total Profit from sales	£6.241.32		+£0
Average monthly cash profit	£326.01	(9.0%)	-£3.40
(Sold stocks profit + Dividends - Fees / Months)

Back into the black, a whopping increase in potential profits slightly marred by OPTI:Optibiotix deepening in loss, but not enough to spoil the party.

Volatile? You betcha!

The SIPP looks like this after week 81

			Weekly Change
Portfolio cost	£17,853.50		+£0
Portfolio sell value (bid price - commission)	£20,159.01	(12.9%%)	+£278.84
Potential profits	£3,484.99		+£525.37
Yr 2 Dividends	£294.95		+£0
Yr 2 Profit from sales	£1,596.81		+£0
Yr 2 Average monthly cash profit	£275.13	(18.5%)	-£9.83
Total Dividends	£708.15		+£0
Total Profit from sales	£3,946.67		+£0
Average monthly cash profit	£243.61	(16.4%)	-£3.04
(Sold stocks profit + Dividends - Fees / Months)

Same story as the main account, with big jump in profits off-set by deepening OPTI:Optibiotix loss (for now...)

Good good good good good!

I hate this bit - horrid trading account after week 47

			Weekly Change
Portfolio cost	£486.05		+£0
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£321.65	(-33.8%)	-£13.90
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£2.11	(-5.2%)	+£0.04
(Sold stocks profit + Dividends - Fees / Months)

What a waste of space. Move along please, nothing to see here...

Pleh!

The end appears to be even more nigh for AFPO:African Potash following today's AGM when they agreed to issue another 221 million shares to buy out 21% of Advanced Agricultural Holding. This was announced back in March, but then in April they announced the reverse takeover of Onshore Energy Ltd, a company of which Executive Chairman Chris Cleverly is a director and shareholder. All this acquisition, but no sign of revenue generation?

Guess what else happened today? Corporate Advisor Peterhouse Corporate Finance resigned with immediate effect. I wonder why?

I think ShareProphets are planning a legal action against the company, and I'm almost tempted to join in, but I think I'll just add it to my list of hard-learned lessons along with the AFG:Aquatic Food disaster. I'll have a £700 hole in my performance stats if they go bust, but it will also reduce my paper deficit by £700.

JLP:Jubilee Platinum announced Hernic is at full production this week. The share price tweaked by a mere 3% so I don't hold out much hope that these are going to re-rate soon. All the good news that could possibly come has come, and yet here we sit making a £207 loss. I think we're stuck in the 4p arena until there's so much cash they can announce a dividend, or something radical happens with Tjate.

KIBO:Kibo Mining didn't drop in value this week after an RNS to say the various licenses are imminent. I think this one could go mad once they come, and I'm still satisfied it will do well - but where are the free Katoro Mining shares?

OPTI:Optibiotix announced the first LP_LDL^® deal this week. They already had a deal to supply 100,000 capsules to HLH Biopharma, so it's not surprising they got in first with a longer term contract. The question is, how quickly will the other interested parties sign contracts now? We're told that when they do, the house brokers can start estimating some revenue. Could that finally free the share price from this 60-70p range? We shall see...

Week 96 Review - Buffer narrows but could have been worse

I was expecting the worst after the election results, and maybe there's still a risk of a delayed reaction, but losses mid-week were much higher than by the end of the week so there was quite a recovery. Combined portfolio value ended up down by £532 so the buffer has narrowed to £1,755 and overall value stands at £63,433

Once again there were no double-digit risers or fallers. Worst performer was AMYT:Amryt Pharma which dropped 9%. That alone accounted for the whole of this week's loss, plus some.

Share of the Week goes to OPTI:Optibiotix which only climbed 4%, but that was enough to counter all the other losses across the portfolio.

The gap gets worryingly narrow

The combined share and ISA accounts look like this

			Weekly Change
Portfolio cost	£43,339.81		+£0
Portfolio sell value (bid price - commission)	£43,217.87	(-0.3%)	-£722.81
Potential profits	£5,193.28		-£538.00
Yr 2 Dividends	£486.29		+£0
Yr 2 Profit from sales	£2,401.06		+£0
Yr 2 Average monthly cash profit	£280.67	(7.8%)	-£6.90
Total Dividends	£1,154.22		+£0
Total Profit from sales	£6.241.32		+£0
Average monthly cash profit	£329.41	(9.1%)	-£3.64
(Sold stocks profit + Dividends - Fees / Months)

I've squeezed the table up a bit as the % figure for the performance could easily fit on the same line. Not sure why it took this long to work that out! The portfolios went back into the red, with most of the drop being due to decreasing AMYT:Amryt Pharma profits, but there were lots of other little losses contributing too. No contribution from IQE:IQE this week as the price stayed the same. Sales and dividend performance down to 9.1% so well below my 10% target. I just don't have anything to sell that I don't want to keep longer term.

Every time the green line gets above the red, down it goes again

The SIPP looks like this after week 80

			Weekly Change
Portfolio cost	£17,853.50		+£384.79
Portfolio sell value (bid price - commission)	£19,880.17	(11.4%%)	+£217.56
Potential profits	£2,959.62		+£140.95
Yr 2 Dividends	£294.95		+£294.95
Yr 2 Profit from sales	£1,596.81		+£0
Yr 2 Average monthly cash profit	£284.96	(19.2%)	+£35.57
Total Dividends	£708.15		+£294.95
Total Profit from sales	£3,946.67		+£0
Average monthly cash profit	£246.65	(16.6%)	+£12.64
(Sold stocks profit + Dividends - Fees / Months)

Lots of action to report this week thanks to some generous dividends. CAML:Central Asia Metals, which is the best run company I invest in, paid out a socking £213.40, taking the total dividends for this share to £473.73. Without the dividends this share is returning 36% on my original investment. With the dividends it's up by 50%. I really should get more in my SIPP while the price is depressed slightly, as  it was 250p back in February and is now only 220p with a P/E ratio of only 11.9, a recent expansion which will increase production, a huge pile of cash and no debt.

The other dividend was £81.56 from LGEN:Legal & General. A proper safe pension share!

There was some cash lying around in the account too so I took the opportunity to top up my OPTI:Optibiotix holding while they're subject to another dip. I was able to get another 520 shares at 71.7p costing £374.79. The timing was good, as the purchase price has now gone to 74p and I'm hoping time is running out to be able to get these at below 100p.

The sell value increased slightly over and above the extra money put in. That was all down to 4% rises in both OPTI:Optibiotix and LGEN:Legal & General, with a 3% dip in ARL:Atlantis Resources and 5% dip in TRX:Tissue Regenix reducing the gains.

The dividends lift average monthly performance by £12.64 a month and help keep this a spectacularly healthy figure.

Not as big a gap as a few months ago, but enough to offset the performance of the other accounts and keep the combined portfolios in the black.

The dreaded trading account looks looks this after week 46

			Weekly Change
Portfolio cost	£486.05		+£0
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£335.55	(-28.99%)	-£28.99
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£2.15	(-5.3%)	+£0.05
(Sold stocks profit + Dividends - Fees / Months)

The only remaining share in this account is REDS:RedstoneConnect, which did a 1 for 100 consolidation this week. Rather than encouraging more investors, it contributed to a 6% decline resulting in my brave attempt at short term trading now being down by nearly 30% and basically an unmitigated disaster. Glad I'm just playing with £500!

I took out the KIBO:Kibo Mining shares too early else I could have aimed at creating a symmetrical graph, which would have been more fun than trying to make any money has been.

So the election is over and the Tory loony wing have power over the fragile majority which will crumble if the DUP aren't kept happy. Great - nice one Teresa, that's really going to improve our chances of reducing the impact of Brexit. Part of me is tickled that such an arrogant, opportunist attempt at grabbing a big majority has failed so badly. The optimist in me hopes that there will be a need for consensus and we can approach Brexit negotiations with a unified UK team, but that would be too much of a culture shock for our petty name-calling politics.

No news expected next week, so it's going to be a case of continued hope that OPTI:Optibiotix might announce what's happening with SBTX:Skinbiotherapeutics share distribution, or some signed contracts following the launch of LP_LDL^®at Vitafoods in May.

There's also an announcement due from JLP:Jubilee Platinum in June to confirm production at Hernic is fully ramped up, and anything that mentions earnings may reverse the current share price slide. Any news on what the hell is going on a Tjate would also help, as the value of that asset is completely ignored by the current share price, despite the obtaining of a mining licence. Let's see what the week has in store...

Week 95 Review - Not great

A pretty poor week, with no double-digit fallers or risers but some significant losses in big holdings like OPTI:Optibiotix which is a trader's dream at the moment, dropping 7% this week. The effect was a drop in combined portfolio value of £1,248.74 with total value £63,583 and £2,288 in the black.

Worst performer this week was OPTI:Optibiotix, but AMYT:Amryt Pharma wasn't far behind, dropping 6%. Between them, these two are responsible for most of the drop in portfolio value.

Share of the Week was IKA:Ilika, rising 9% but still 24% down on my original purchase price.

Last week's optimism was short-lived, and heaven knows what's going to happen next Thursday!

			Weekly Change
Portfolio cost	£43,339.81		+£499.98
Portfolio sell value (bid price - commission)	£43,940.68	(+1.4%)	-£768.09
Potential profits	£5,731.28		-£351.33
Yr 2 Dividends	£486.29		+£27.35
Yr 2 Profit from sales	£2,401.06		+£0
Yr 2 Average monthly cash profit	£287.57		-£4.03
Yr 2 Avg annual % of current portfolio cost	8.0%
Total Dividends	£1,154.22		+£27.35
Total Profit from sales	£6.241.32		+£0
Average monthly cash profit	£333.05		-£2.28
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	9.2%

Portfolio cost went up because I was so fed up of my trading account being rubbish, I moved my KIBO:Kibo Mining shares out into my share account, as I'd much rather keep these long term now I have them. Value was clobbered by £768 of which about half was reduced profits and half deepened loss. A nice £27.35 dividend arrived from LOOK:Lookers, but I still don't forgive them for being 28% down and never recovering from Brexit. The dividend reduced the slip in monthly performance a tad.

Still in the black, but in great danger of going under by the end of next week.

The SIPP looks like this after week 79

			Weekly Change
Portfolio cost	£17,468.71		+£0
Portfolio sell value (bid price - commission)	£19,277.82	(+10.4%)	-£509.37
Potential profits	£2,818.67		-£263.53
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£1,596.81		+£0
Yr 2 Average monthly cash profit	£49.39		-£9.59
Yr 2 Avg annual % of current portfolio cost	17.1%
Total Dividends	£413.19		+£0
Total Profit from sales	£3,946.67		+£0
Average monthly cash profit	£234.01		-£3.00
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	16.1%

Almost the same story as the other portfolio, with £509 drop in value, of which just over half was dropping profits and just under half deepening losses

Back to the narrow gap

The trading account looks like this after week 45

			Weekly Change
Portfolio cost	£486.05		-£499.98
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£364.54	(-25.0%)	+£28.73
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£2.20		+£0.05
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	-5.4%

Ha! Revenge is mine! That'll teach it for being so rubbish - punished by having half the value wiped out. Now it's back to the "let's see what I can do with £500" game, and KIBO:Kibo Mining is safely tucked away for the long term.

REDS:RedstoneConect is all that's left now, and that ticked up a fraction to leave the account £28 better off if you discount the removed shares.

At least it's making an interesting pattern - about the only interesting thing associated with this account!

The general election is bound to cause havoc next week, and I have a bad feeling there's going to be a horrible crash or something. Tragically I have no funds free to take advantage of any 1-day blips, so will just have to ride the storm.

Very disappointing annual results from TRX:Tissue Regenix today. Although income was up by 77% to £1.4 million, their cash burn is so massive they still posted a loss of £11 million. With only £8.2 million in cash, that's not enough to last the next year unless revenues increase significantly. There is a chance revenues will increase significantly, but I had hoped for this to have already started. I guess I'm being a bit harsh, as some of the deals to get accepted in USA were towards the end of the year and too late for the results, so I await the next trading statement eagerly. The shares dropped by 5% on the news.

I rather desperately need OPTI:Optibiotix to announce something and get back up above 80p. This is so volatile at the moment, not helped the the Yorkshire Seedcorn Fund flogging another 500,000 shares last week and not enough people buying them to save the share price. They still have 10 million left to sell, which is a bit of a worry.

I'm getting increasingly frustrated by the lack of news on free SBTX:SkinBiotherapeutics shares to OPTI:Optibiotix holders. This has been left hanging for a long time, with assertions that long term holders will be rewarded over and above day traders coming to nothing. I will sleep far better at night knowing what the plans are for this. Meanwhile, there was lots of enthusiasm after Vitafoods so an announcement of a contract next week would really help get things back into profit.

OK - deep breath and launch into election week...

Week 94 Review

A relatively quiet week, especially compared to last week. The combined portfolios ended up £473.60 better off with a total value of £64,831 and standing £3,537 in the black.

There were no double-digit losers, but with OPTI:Optibiotix dropping 6%, SKIN:SkinBiotherapeutics dropping 9% and KIBO:Kibo Mining dropping 5% it could easily have been a red week. However, this week's only double-digit riser and Share of the Week was AMYT:Amryt Pharma which soared 22%, taking paper profits to £2,445 and making it my 2nd best performer after IQE:IQE. The 4p rise that lifted it to 26p was worth over £1,300, and with brokers suggesting 60p+ as target price, this could quite quickly add another £14,000 over the next few years.

I ought to give GVC:GVC Holdings a mention too. A 7% rise this week saw the price go to 811p, so with my original purchase price of 420p this has nearly doubled. If I hadn't bedded it into my ISA and taken a chunk of the profits from paper to real, this would be up there competing with AMYT:Amryt Pharma for 2nd best performer, and it's paid out £142 in dividends too.

The gap is back!

The ISA and share accounts look like this

			Weekly Change
Portfolio cost	£42,839.83		+£269.69
Portfolio sell value (bid price - commission)	£44,208.79	(+3.2%)	+£827.47
Potential profits	£6,082.61		+£1,586.90
Yr 2 Dividends	£458.94		+£0
Yr 2 Profit from sales	£2,401.06		+£0
Yr 2 Average monthly cash profit	£291.60		-£7.11
Yr 2 Avg annual % of current portfolio cost	8.2%
Total Dividends	£1,126.87		+£0
Total Profit from sales	£6.241.32		+£0
Average monthly cash profit	£335.83		-£3.61
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	9.4%

I added £269 to buy some more CMCL:Caledonia Mining before the share consolidation. Potential profits were up a massive £1,586 thanks to AMYT:Amryt Pharma and GVC:GVC Holdings, but half of that was zapped by the increased losses I mentioned above. No sales or dividends, so a slight tick down in performance and I'm still conscious I need to get the average back above 10%.

After the panic of 2 weeks ago, the recovery has been most satisfying, and don't forget there's the £1,100 loss from the AFG:Aquatic Food disaster lost in the middle of that lot somewhere, causing barely a ripple in the lines.

The SIPP looks like this after week 78

			Weekly Change
Portfolio cost	£17,468.71		+£0
Portfolio sell value (bid price - commission)	£19,787.19	(+13.3%)	-£315.77
Potential profits	£3,082.20		-£277.42
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£1,596.81		+£0
Yr 2 Average monthly cash profit	£258.98		-£10.36
Yr 2 Avg annual % of current portfolio cost	17.8%
Total Dividends	£413.19		+£0
Total Profit from sales	£3,946.67		+£0
Average monthly cash profit	£237.01		-£3.08
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	16.3%

The pension didn't have the protection of AMYT:Amryt Pharma and so the drop in OPTI:Optibiotix did a lot of damage. There were small drops in the loss-making shares too, which dragged the portfolio value down despite another tick up for IQE:IQE.

If I can maintain this gap for a while I'll be happy.

The dreaded trading account looks like this after week 44

			Weekly Change
Portfolio cost	£986.03		+£0
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£835.79	(-15.2%)	-£38.10
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£2.25		+£0.05
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	-2.87%

What an unmitigated disaster. Nearly a year and I've managed to make a loss from sales thanks to pulling my JLP:Jubilee Platinum shares out of this account into my ISA and the other 2 absolutely refuse to get into profit while I sit impotently waiting for something interesting to do. I'm such a shit trader! Glad this experiment is with a small percentage of my savings.

Pants!

Next week is a short week with the bank holiday, and none of my shares are due to report so it could be a quiet one as we await the general election. It would be nice if AMYT:Amryt Pharma could do an IQE:IQE and slowly creep upwards, as that will protect my buffer from volatility elsewhere. There's a risk of profit taking though, as the FAST:Fastnet Equity reverse takeover price was 24p so the long-term holders that might be feeling impatient could start to bale as we climb towards 30p. In my opinion that would be rather premature, as this company has potential to deliver astounding shareholder value for those invested from the start.

OPTI:Optibiotix continues to perplex. News of contracts coming after the Vitafoods exhibition could give us a boost, and the long-awaited news of free SKIN:SkinBiotherapeutics shares would be most welcome. Murmurings on the bulletin board suggest that the attempts to reward long-term holders over and above day traders are not going to be realised, which is a shame, but I'd really like to know what we're going to get so I can make some decisions on whether to buy any more SKIN:SkinBiotherapeutics shares on the market while they are below my initial buying price.

Forced to buy more gold

There was an RNS this morning from CMCL:Caledonia Mining to say they were planning to list on the New York Stock Exchange. As the minimum value per share is $2 with a preference for $5 they are doing a share consolidation prior to the listing.

At first this seemed fine, until I read the details.

It's one share for every five, however, rather than just do that they are initially doing one for every hundred, and then multiplying that by 20.

Yeah right - I had 737, so after paying 135p per share I'm going to let 37 of them sell for 94p - I think not!

I loaded £200 into my ISA from my current account and bought 263 at 98p costing £269.69. This brings my total up to a nice round 1,000 shares. That will go down to 10 on the initial consolidation, then up to 200 on the second phase, with no loss of shares.

The effect was to bring my average price down from 135p to 125.3p so I'm hoping the new liquidity of listing in America along with a gold rally will get these back to profit. I did rather buy on a spike! Although miffed at the price I originally paid, I'm not too concerned as the P/E ratio is just 10.7 and that's based on the price of gold last year. With production ramping up a P/E ratio of 15 would be worth about 350p, and while there's risk with their country of operation which will likely keep the price down, my target is at least 250p, around double what I paid.

I do like this as a gold share, with a quarterly dividend of £8 just ticking along nicely. It's not as good a return as PAF:Pan African Resources but I think a bit less risky, despite being in Zimbabwe. Having said that, the PAF:Pan African Resources dividend is so good, I'm tempted to get back in just before the October ex-date if the price doesn't go mad.

KAT:Katoro Gold dropped 2.5% today. I'm keeping an eye on this one, but as I'm expecting a decent chunk of free shares from KIBO:Kibo Mining I won't be buying any. However, if the price drops much further it might be one for the trading account!

At the halfway point, this week is looking OK. The combined portfolios are up by £395, with AMYT:Amryt Pharma doing particularly well. OPTI:Optibiotix has slipped a bit else things would be looking much better.

I was quite shocked to see VEC:Vectura has dropped to 120p on the news that the Americans have rejected their joint bid with HIK:Hikma Pharma to sell a generic version of Advair, until now protected by patents. The share price has dropped from 150p to 120p which seems a bit of an over-reaction. I sold my holding at 153p for a £89 loss, but am keeping an eye on this, as although the rejection will cost them this year, they are likely to get approval eventually so a recovery seems on the cards. The question is how much lower will it go beforehand?

I do like to keep track of my old shares. Sometimes it's painful, when I see TON:Titon Holdings at 165p after I sold at 101p and 91p, although that was still 15% profit. Sometimes I'm filled with relief that I got out in time, like with AFG:Aquatic Food which has dropped even further, or RCI:Rapidcloud which has vanished but gave me an 11.4% profit. AVM:Avocet Mining was another close one, yielding just a 3.5% profit but that would now be a 50% loss. It's amazing how many of them are pretty much the same price as when I sold though.

Right - time to don my Man Utd top, crack open a beer and prepare for the most important game we've had for many a year!

Week 93 Review - Best ever week?

What an amazing week. the review is late as I've been on holiday, but there was much giggling as I checked my portfolio and watched OPTI:Optibiotix climb relentlessly back into profit. Nemesis Share - what Nemesis Share? The combined portfolios ended up a staggering £3,185.84 better off than last week, £3,063 in the black with a value of £64,088.48. Woohoo!!

No double-digit losers this week, and both double-digit risers are related. OPTI:Optibiotix made a triumphant return to profit and rewarded all the 64p purchases by leaping 15% to 77p and is now £956 in profit. The worm has well and truly turned!

Share of the Week is an offspring of OPTI:Optibiotix, with SBTX:SkinBiotherapeutics climbing 24%. This is still 10% down on my purchase but on the way to recovery.

That's more like it!

The ISA and share accounts look like this

			Weekly Change
Portfolio cost	£42,570.14		+£13.23
Portfolio sell value (bid price - commission)	£43,111.63	(+1.3%)	+£2,128.18
Potential profits	£4,495.71		+£443.29
Yr 2 Dividends	£458.94		+£93.90
Yr 2 Profit from sales	£2,401.06		+£0
Yr 2 Average monthly cash profit	£298.71		+£2.71
Yr 2 Avg annual % of current portfolio cost	8.4%
Total Dividends	£1,126.87		+£93.90
Total Profit from sales	£6.241.32		+£0
Average monthly cash profit	£338.94		+£0.74
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	9.6%

Portfolio cost went up due to the open offer for RDT:Rosslyn Data. Although I don't hold out a huge amount of hope, the chance of increasing my holding by 10% for hardly any money and no commission had to be taken and brought the average price down from 17.52p to 15.85p. They are still 70% down though.

A staggering increase in value of £2,128 has brought the accounts back into the black. Hopefully this time it will last longer than a week! Of that, only £443 was increased profit. Most of it was reduction in loss for OPTI:Optibiotix, SBTX:SkinBiotherapeutics and KIBO:Kibo Mining.

There were lots of dividends this week, with £72.86 from GVC:GVC Holdings, £13.74 from TW.:Taylor Wimpey and £7.30 from BDEV:Barratt Developments, adding up to £93.90. This allowed the average monthly performance to creep up instead of the usual dip. I'm still below the target 10% though.

You might call this one volatile! All I can do is hope the green holds above the red for a while this time.

The SIPP looks like this after week 77

			Weekly Change
Portfolio cost	£17,468.71		+£0
Portfolio sell value (bid price - commission)	£20,102.96	(+15.1%)	+£1,061.39
Potential profits	£3,359.62		+£725.26
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£1,596.81		+£0
Yr 2 Average monthly cash profit	£269.34		-£11.23
Yr 2 Avg annual % of current portfolio cost	18.5%
Total Dividends	£413.19		+£0
Total Profit from sales	£3,946.67		+£0
Average monthly cash profit	£240.09		-£3.16
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	16.5%

A superb £1,061 rise in value, £725 of which were increased profits and most of that was OPTI:Optibiotix, with a contribution from IQE:IQE which continued to climb, although much slower than recently. Performance took the usual slight dip due to no sales or dividends.

The gap isn't the widest it's been, but not far off.

The trading account looks like this after week 43

			Weekly Change
Portfolio cost	£986.03		+£0
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£873.89	(-11.4%)	-£3.73
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£2.30		+£0.06
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	-2.8%

The increase in KIBO:Kibo Mining was offset by the drop in REDS:RedstoneConnect resulting in a drop of £3.73.

I think you can call this consistent - consistently rubbish!

No time to ponder what might happen next week as it's already next week now. A luke-warm start to the week today, but nothing to put the new super-buffer under threat.